338 related articles for article (PubMed ID: 33677142)
21. Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy.
Lee S; Lee YJ; Kong J; Ryu HW; Shim YK; Han JY; Woo H; Kim SY; Cho A; Lim BC; Chae JH
Brain Dev; 2022 Apr; 44(4):287-293. PubMed ID: 35033405
[TBL] [Abstract][Full Text] [Related]
22. Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec.
Matesanz SE; Curry C; Gross B; Rubin AI; Linn R; Yum SW; Kichula EA
J Child Neurol; 2020 Oct; 35(11):717-723. PubMed ID: 32515646
[TBL] [Abstract][Full Text] [Related]
23. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy.
Schwartz M; Likhite S; Meyer K
Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905
[TBL] [Abstract][Full Text] [Related]
24. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
Chand D; Mohr F; McMillan H; Tukov FF; Montgomery K; Kleyn A; Sun R; Tauscher-Wisniewski S; Kaufmann P; Kullak-Ublick G
J Hepatol; 2021 Mar; 74(3):560-566. PubMed ID: 33186633
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: A systematic review and meta-analysis.
Yang D; Ruan Y; Chen Y
J Paediatr Child Health; 2023 Mar; 59(3):431-438. PubMed ID: 36722610
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1.
Oechsel KF; Cartwright MS
Muscle Nerve; 2021 Oct; 64(4):487-490. PubMed ID: 34287987
[TBL] [Abstract][Full Text] [Related]
27. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy.
D'Silva AM; Holland S; Kariyawasam D; Herbert K; Barclay P; Cairns A; MacLennan SC; Ryan MM; Sampaio H; Smith N; Woodcock IR; Yiu EM; Alexander IE; Farrar MA
Ann Clin Transl Neurol; 2022 Mar; 9(3):339-350. PubMed ID: 35170254
[TBL] [Abstract][Full Text] [Related]
28. Polysomnography findings and respiratory muscle function in infants with early onset spinal muscular atrophy after gene replacement as monotherapy: A prospective study.
Barrois R; Griffon L; Barnerias C; Gitiaux C; Desguerre I; Fauroux B; Khirani S
Sleep Med; 2024 Jul; 119():335-341. PubMed ID: 38749258
[TBL] [Abstract][Full Text] [Related]
29. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L
Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095
[TBL] [Abstract][Full Text] [Related]
30. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.
Thomsen G; Burghes AHM; Hsieh C; Do J; Chu BTT; Perry S; Barkho B; Kaufmann P; Sproule DM; Feltner DE; Chung WK; McGovern VL; Hevner RF; Conces M; Pierson CR; Scoto M; Muntoni F; Mendell JR; Foust KD
Nat Med; 2021 Oct; 27(10):1701-1711. PubMed ID: 34608334
[TBL] [Abstract][Full Text] [Related]
31. Vaccination proposal for patients on onasemnogene abeparvovec therapy.
Dobner S; Kulcsár A; Liptai Z; Vojnisek Z; Constantin T; Szabó L
Eur J Paediatr Neurol; 2024 Mar; 49():95-99. PubMed ID: 38457958
[TBL] [Abstract][Full Text] [Related]
32. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy.
Kichula EA; Proud CM; Farrar MA; Kwon JM; Saito K; Desguerre I; McMillan HJ
Muscle Nerve; 2021 Oct; 64(4):413-427. PubMed ID: 34196026
[TBL] [Abstract][Full Text] [Related]
33. Necrotizing Enterocolitis following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series.
Gaillard J; Gu AR; Neil Knierbein EE
J Pediatr; 2023 Sep; 260():113493. PubMed ID: 37211209
[TBL] [Abstract][Full Text] [Related]
34. Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy.
Ferrante L; Melendez-Zaidi A; Lindsey W; Lotze T
Muscle Nerve; 2022 Aug; 66(2):E8-E10. PubMed ID: 35616550
[No Abstract] [Full Text] [Related]
35. Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma).
Ogbonmide T; Rathore R; Rangrej SB; Hutchinson S; Lewis M; Ojilere S; Carvalho V; Kelly I
Cureus; 2023 Mar; 15(3):e36197. PubMed ID: 37065340
[TBL] [Abstract][Full Text] [Related]
36. Gene therapy for spinal muscular atrophy: the Qatari experience.
Ali HG; Ibrahim K; Elsaid MF; Mohamed RB; Abeidah MIA; Al Rawwas AO; Elshafey K; Almulla H; El-Akouri K; Almulla M; Othman A; Musa S; Al-Mesaifri F; Ali R; Shahbeck N; Al-Mureikhi M; Alsulaiman R; Alkaabi S; Ben-Omran T
Gene Ther; 2021 Nov; 28(10-11):676-680. PubMed ID: 34276047
[TBL] [Abstract][Full Text] [Related]
37. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy.
Kirschner J; Butoianu N; Goemans N; Haberlova J; Kostera-Pruszczyk A; Mercuri E; van der Pol WL; Quijano-Roy S; Sejersen T; Tizzano EF; Ziegler A; Servais L; Muntoni F
Eur J Paediatr Neurol; 2020 Sep; 28():38-43. PubMed ID: 32763124
[TBL] [Abstract][Full Text] [Related]
38. Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial.
Shell RD; McGrattan KE; Hurst-Davis R; Young SD; Baranello G; Lavrov A; O'Brien E; Wallach S; LaMarca N; Reyna SP; Darras BT
Neuromuscul Disord; 2023 Aug; 33(8):670-676. PubMed ID: 37455203
[TBL] [Abstract][Full Text] [Related]
39. Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience.
Tokatly Latzer I; Sagi L; Lavi R; Aharoni S; Bistritzer J; Noyman I; Ginsburg M; Lev-Or A; Katzenellenbogen S; Nevo Y; Fattal-Valevski A
Pediatr Neurol; 2023 Jul; 144():60-68. PubMed ID: 37149951
[TBL] [Abstract][Full Text] [Related]
40. Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam.
Tosi M; Catteruccia M; Cherchi C; Mizzoni I; D'Amico A
Acta Myol; 2022; 41(3):117-120. PubMed ID: 36349185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
